Delcath Systems Inc (DCTH)

$13.20 +0.29 (2.25%)
Market Cap 455.69M
Revenue (ttm) 85.23M
Net Income (ttm) 2.70M
EPS (ttm) N/A
PE Ratio 1,291.00
Forward PE N/A
Profit Margin 3.17%
Debt to Equity Ratio 0.00
Volume 337,900
Avg Vol 507,438
Day's Range N/A - N/A
Shares Out 34.52M
Stochastic %K 98%
Beta 0.49
Analysts Strong Sell
Price Target $22.40

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices
Sector: Healthcare
Phone: 212 489 2100
Fax: 212 489 2102
Address:
566 Queensbury Avenue, Queensbury, United States
Doozio
Doozio Jul. 4 at 9:38 PM
$DCTH ENTA 🐒🍌🧠⏰♾️
0 · Reply
alexpitti
alexpitti Jul. 2 at 10:22 PM
happy 4th of july $STXS $DCTH $ABEO $ADBE $MIST
2 · Reply
mar99
mar99 Jul. 2 at 8:01 PM
$DCTH It was just 2 weeks ago Dcth was fighting to finally close over 12 as everyday it went over 12 and they took it back down until finally closing over 12. Now less than 2 weeks later after several tries over 13 we close over 13 and we are closing in on 52 week high from August. Nice to see the way this is progressing and nice way to go into the long weekend.
1 · Reply
Playthegame06
Playthegame06 Jun. 30 at 12:52 AM
$DCTH Last day of 2 Qtr......Let's hope and pray Revs are north of $25MM.
2 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Jun. 27 at 3:04 PM
$DCTH 📚 Why $DCTH is a high-conviction play right now: Delcath is commercializing HEPZATO KIT, a breakthrough liver-directed chemotherapy system for unresectable hepatic metastases (ocular melanoma and beyond). FY2026 revenue guidance is at least $100M with strong procedure growth and expanding adoption. Recent clinical data and ASCO updates continue to build the case. Big Name Institutional Buyers: Rosalind Advisors, BlackRock, Vanguard, Bank of America, and other institutions own over 50% of the company with ongoing accumulation. Wanna know more hit that follow button 🤝
0 · Reply
alexpitti
alexpitti Jun. 26 at 11:54 PM
$DCTH nothing is up. if you look at the volume numbers, $SI $STXS $ABEO all had way above normal volume
2 · Reply
CosmicMiner
CosmicMiner Jun. 26 at 8:08 PM
$DCTH up 5% today. Tracking the price action and volume on this move.
0 · Reply
michaelsott
michaelsott Jun. 26 at 8:03 PM
$DCTH HMMMMM I wonder what is up???????? Volume is way up the normal.
1 · Reply
BreakoutLife
BreakoutLife Jun. 26 at 1:32 PM
$DCTH has the textbook Wave 2 support setup. 5 waves up for Wave 1, 3 waves down (ABC) for Wave 2. It held the 0.618 Fib and 200 WMA perfectly, and now it's making higher highs above all MAs while recapturing the 50 WMA. Very little resistance left on the way to the Wave 3 target at $34 (current price $12). Study this setup. This is where you show conviction.
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 24 at 6:33 PM
$ETH.X at $1600 is a buy $DCTH at $13 is a buy $GRRR at $16 is a buy $NVO at $46 is a buy ??? at $1.5 is a buy All of these have not been following the US market In different cycles and are not in parabolic moves right now Are you going to miss out again?
1 · Reply
Latest News on DCTH
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

2026-05-26T20:05:59.000Z - 5 weeks ago

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 26, 2026, 4:01 PM EDT - 5 weeks ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 4:01 PM EDT - 7 weeks ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T14:11:04.000Z - 2 months ago

Delcath Systems presents new data on M-PHP at ESMO

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:35:47.000Z - 2 months ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

2026-05-07T13:34:32.000Z - 2 months ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Earnings Call Transcript: Q1 2026

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Earnings release: Q1 2026

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems Quarterly report: Q1 2026

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 23, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Apr 6, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems management to meet with Craig Hallum

2026-04-02T14:44:15.000Z - 3 months ago

Delcath Systems management to meet with Craig Hallum

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Apr 1, 2026, 8:30 AM EDT - 3 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

2026-03-03T13:43:26.000Z - 4 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T18:26:15.000Z - 4 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:50.000Z - 4 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

2026-02-26T13:33:07.000Z - 4 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Annual report: Q4 2025

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 4 months ago

Delcath Systems Earnings release: Q4 2025

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 8:00 AM EST - 4 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Feb 12, 2026, 8:00 AM EST - 5 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 27, 2026, 8:05 AM EST - 5 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T15:30:16.000Z - 6 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

2026-01-09T13:15:29.000Z - 6 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 9, 2026, 8:05 AM EST - 6 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Delcath Systems publishes results from subgroup analyses of FOCUS study

2025-12-31T13:15:08.000Z - 6 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 31, 2025, 8:00 AM EST - 6 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems announces publication of CHEMOSAT study

2025-12-03T21:05:29.000Z - 7 months ago

Delcath Systems announces publication of CHEMOSAT study

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 7 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems authorizes $25M buyback program

2025-11-20T21:05:49.000Z - 8 months ago

Delcath Systems authorizes $25M buyback program

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 20, 2025, 4:01 PM EST - 8 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems publishes review of Hepzato Kit

2025-11-18T14:38:40.000Z - 8 months ago

Delcath Systems publishes review of Hepzato Kit

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 18, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Delcath announces publication supporting early use of liver-directed therapy

2025-11-13T14:21:28.000Z - 8 months ago

Delcath announces publication supporting early use of liver-directed therapy

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 13, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:01 PM EST - 8 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Quarterly report: Q3 2025

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 8 months ago

Delcath Systems Earnings release: Q3 2025

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Nov 4, 2025, 8:00 AM EST - 8 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Delcath Systems price target lowered to $20 from $24 at Craig-Hallum

2025-10-21T13:05:37.000Z - 9 months ago

Delcath Systems price target lowered to $20 from $24 at Craig-Hallum

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 21, 2025, 8:30 AM EDT - 9 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Clear Street ups Delcath target, sees opportunity on selloff

2025-10-20T16:00:49.000Z - 9 months ago

Clear Street ups Delcath target, sees opportunity on selloff

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Delcath Systems Transcript: Study Result

Delcath Systems Press release: Study Result

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Delcath Systems Press release: Study Result

Delcath Systems Slides: Corporate Presentation

Oct 20, 2025, 7:00 AM EDT - 9 months ago

Delcath Systems Slides: Corporate Presentation

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:15 PM EDT - 9 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Oct 18, 2025, 4:13 PM EDT - 9 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 22, 2025, 4:01 PM EDT - 10 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 11:00 AM EDT - 10 months ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Earnings Call Transcript: Q2 2025

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Quarterly report: Q2 2025

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Delcath Systems Earnings release: Q2 2025

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jul 23, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Delcath Systems Slides: Investor Presentation

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q3 2024

Delcath Systems Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Quarterly report: Q3 2024

Delcath Systems Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q3 2024

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Doozio
Doozio Jul. 4 at 9:38 PM
$DCTH ENTA 🐒🍌🧠⏰♾️
0 · Reply
alexpitti
alexpitti Jul. 2 at 10:22 PM
happy 4th of july $STXS $DCTH $ABEO $ADBE $MIST
2 · Reply
mar99
mar99 Jul. 2 at 8:01 PM
$DCTH It was just 2 weeks ago Dcth was fighting to finally close over 12 as everyday it went over 12 and they took it back down until finally closing over 12. Now less than 2 weeks later after several tries over 13 we close over 13 and we are closing in on 52 week high from August. Nice to see the way this is progressing and nice way to go into the long weekend.
1 · Reply
Playthegame06
Playthegame06 Jun. 30 at 12:52 AM
$DCTH Last day of 2 Qtr......Let's hope and pray Revs are north of $25MM.
2 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Jun. 27 at 3:04 PM
$DCTH 📚 Why $DCTH is a high-conviction play right now: Delcath is commercializing HEPZATO KIT, a breakthrough liver-directed chemotherapy system for unresectable hepatic metastases (ocular melanoma and beyond). FY2026 revenue guidance is at least $100M with strong procedure growth and expanding adoption. Recent clinical data and ASCO updates continue to build the case. Big Name Institutional Buyers: Rosalind Advisors, BlackRock, Vanguard, Bank of America, and other institutions own over 50% of the company with ongoing accumulation. Wanna know more hit that follow button 🤝
0 · Reply
alexpitti
alexpitti Jun. 26 at 11:54 PM
$DCTH nothing is up. if you look at the volume numbers, $SI $STXS $ABEO all had way above normal volume
2 · Reply
CosmicMiner
CosmicMiner Jun. 26 at 8:08 PM
$DCTH up 5% today. Tracking the price action and volume on this move.
0 · Reply
michaelsott
michaelsott Jun. 26 at 8:03 PM
$DCTH HMMMMM I wonder what is up???????? Volume is way up the normal.
1 · Reply
BreakoutLife
BreakoutLife Jun. 26 at 1:32 PM
$DCTH has the textbook Wave 2 support setup. 5 waves up for Wave 1, 3 waves down (ABC) for Wave 2. It held the 0.618 Fib and 200 WMA perfectly, and now it's making higher highs above all MAs while recapturing the 50 WMA. Very little resistance left on the way to the Wave 3 target at $34 (current price $12). Study this setup. This is where you show conviction.
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 24 at 6:33 PM
$ETH.X at $1600 is a buy $DCTH at $13 is a buy $GRRR at $16 is a buy $NVO at $46 is a buy ??? at $1.5 is a buy All of these have not been following the US market In different cycles and are not in parabolic moves right now Are you going to miss out again?
1 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 24 at 4:00 PM
Selective buy zones - names decoupled from broad US index momentum and trading on their own cycles. $ETH.X at $1600 is a buy $DCTH at $13 is a buy $GRRR at $16 is a buy $NVO at $46 is a buy These names are not tracking the broader US market beta - they’re moving through their own cycle structures driven by sector-specific catalysts and longer-term re-rating dynamics. No parabolic phase yet - just early accumulation / dislocation zones where risk-reward starts to reappear. This type of setup is about patience, not momentum chasing. Sharing framework and levels - no paywall, just structured positioning thinking
0 · Reply
ManyThanks212
ManyThanks212 Jun. 24 at 1:54 PM
$DCTH run
0 · Reply
topstockalerts
topstockalerts Jun. 23 at 9:21 PM
$DCTH this move has a surprisingly mature feel to it.
2 · Reply
Value1008
Value1008 Jun. 23 at 4:05 PM
$DCTH - early yesterday i wondered if the HFT trading bots would take this down for another test of support at the 20dma, as happened on June 11 before rebounding, and sure enough the stock was manipulated down near to that 20dma by yesterday's close. This morning it bounced strongly off that support line and now we see a powerful breakout to the upside. Let's see in coming days where the new support line is. In any case, fundamentals look strong for the longer term investment.
0 · Reply
alexpitti
alexpitti Jun. 22 at 5:12 PM
did you guys see another hospital hit 100 hepzato treatments? $DCTH
1 · Reply
Ratman44
Ratman44 Jun. 18 at 8:00 PM
$DCTH pretty sure every day they update the website with a new center it goes down.
0 · Reply
mar99
mar99 Jun. 18 at 4:28 PM
$DCTH Canaccord reiterated their Buy rating on Dcth. Price target 21.
0 · Reply
alexpitti
alexpitti Jun. 18 at 3:30 PM
$DCTH is columbia an ai data center? If not we are screwed
0 · Reply
pufferfishcapital
pufferfishcapital Jun. 18 at 2:36 PM
$DCTH Columbia University Medical Center just added as 30th active center
0 · Reply
alexpitti
alexpitti Jun. 17 at 7:52 PM
the fed ruined our winning day. wow $MIST $STXS $DCTH $ABEO
2 · Reply
alexpitti
alexpitti Jun. 17 at 3:26 PM
$DCTH there is a major battle for delcath at $12 for whatever reason
0 · Reply
mar99
mar99 Jun. 17 at 3:14 PM
$DCTH Sticking to its normal daily routine today. Run up over 12 followed by selling taking it quickly back below 12. Seems to be the case most every day now. I guess they aren’t ready to let it close over 12 yet. Hopefully that’s coming.
0 · Reply